RCM
RLAY icon

RA Capital Management’s Relay Therapeutics RLAY Stock Holding History

RA Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-717,618
Closed -$16.1M – 78
2022
Q3 		$16.1M Buy
717,618
+168,563
+31% +$3.7M 0.34% 54
2022
Q2 		$9.2M Hold
549,055
– – 0.25% 61
2022
Q1 		$16.4M Hold
549,055
– – 0.36% 57
2021
Q4 		$16.9M Buy
+549,055
New +$17.4M 0.3% 62
2021
Q2 		– Sell
-1,000,000
Closed -$34.6M – 96
2021
Q1 		$34.6M Hold
1,000,000
– – 0.52% 48
2020
Q4 		$41.6M Hold
1,000,000
– – 0.58% 44
2020
Q3 		$42.6M Buy
+1,000,000
New +$38.1M 0.78% 36

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RA Capital Management's RLAY Position: Q4 2022 in Review

RA Capital Management sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 717,618 shares — an estimated $16.1M sold.

RA Capital Management first reported a position in RLAY in Q3 2020 and held it in 7 quarters. The position peaked at $42.6M in Q3 2020. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

  • RA Capital Management reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
  • RA Capital Management sold 717,618 Relay Therapeutics shares in Q4 2022, an estimated $16.1M.
  • RA Capital Management first reported a position in Relay Therapeutics in Q3 2020 and held it in 7 quarters.
  • RA Capital Management's Relay Therapeutics position peaked at $42.6M in Q3 2020.
  • 165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.